PT Kalbe Farma Tbk (Kalbe) has entered a collaboration with PT Amarox Global Pharma (Amarox) to market the new Covid-19 drug, Movfor (Molnupiravir).
The new antiviral drug is indicated to treat Covid-19 patients aged more than 18 years with mild and moderate symptoms, who do not require oxygen administration.
It is also recommended for individuals who do not have the potential to experience severe Covid-19 symptoms based on the latest edition of the Indonesia Covid-19 Management Guidelines.
Molnupiravir received emergency use authorization (EUA) from the National Agency of Drug and Food Control (BPOM RI) in Indonesia and from the US Food and Drug Administration (FDA) to treat Covid-19.
Movfor is said to be the first branded Molnupiravir variant that received EUA from BPOM RI.
On 15 February, Amarox has officially launched the drug in Indonesia.
Amarox general manager Sandeep Sur said: “Refer to result of Clinical Trial Phase III, Molnupiravir is effective on current SARS-CoV-2 variant and has potential to restrain variant Omicron SARS-CoV-2 infection, resulting in 100% viral clearance by RT PCR result on the fifth day.”
Sandeep Sur also stated that Movfor has also been sold and used in India and in some ASEAN countries for the treatment of Covid-19.
Kalbe director Mulia Lie said: “Kalbe has collaborated with Amarox as the main marketing and distribution partner for other Covid-19 antiviral drugs that includes Covifor (Remdesivir) and Fluvir (Oseltamivir) prior to this (press release).
“The collaboration effort to market of Movfor (Molnufiravir) is a continuation of that engagement. Hopefully, these three antiviral drugs will help with the national availability for Covid-19 treatment drugs that is accessible to the greater public.”
With the support of 76 distribution branches in 34 provinces, Kalbe expects to accelerate and improve the access and availability of the drug to treat Covid-19 in Indonesia.